SC83288
SC83288
is an intravenous treatment of severe malaria
Under development by Sumaya Biotech GmbH & Co KG (Sumaya), Heidelberg, Germany
SC83288
Sumaya Biotech GmbH & Co KG (Sumaya) was founded as a spin-out from the University of Heidelberg by Prof. Dr. Hermann Bujard as its scientific founder and Dr. Ernst Böhnlein the current Managing Director on 23rd March 2015. The focus of the clinical stage biotech company is on treatments against malaria.
In 2018, Prof. M. Lanzer joined Sumaya with his SC83288 anti-malarial compound after his publication in Nature Comms 2017. SC83288 is a fast-acting compound that could eliminate a P. falciparum infection in a humanized SCID mouse model. Importantly, SC83288 targets early and late blood stages, by inhibiting DNA replication and merozoite egress. Sumaya is planning to clinically develop SC83288 as an intravenous treatment of severe malaria. In pre-clinical toxicology studies, SC83288 did not show any apparent toxicology, in particular there were no signs of hemolytic activity. Furthermore, SC83288 has been shown to be resistance breaking. Due to its novel mode of action, it can be combined with other established, slow-and fast-acting drugs as combination therapy. Based on its better side-effect profile, Sumaya will develop SC83288 as first or second line treatment of severe malaria.
The EUMF funding supports Sumaya’s efforts to finance the regulatory approval for first in human study of SC83288.